Corporate Counsel/Senior Corporate Counsel - Transactions
About the job
- A JD from an accredited law school and admission to practice in at least one U.S. jurisdiction are required.
- At least five years of experience with complex biotechnology contracting is required; experience with commercial-stage cell and gene therapy companies is ideal.
- Ability to manage multiple overlapping, high-stakes agreements to completion on tight timelines.
- Ability to collaborate with team members on a diverse range of projects.
- High degree of professional ethics and integrity.
- Sound judgment and ability to quickly analyze different sources of information.
- Practical and business-minded approach, with ability to recognize, assess, and respond to urgent matters with timely, pragmatic, and clear solutions.
- Exceptional written and verbal communication skills.
- Draft and negotiate high-stakes agreements supporting anticipated product launches, including complex commercial contracts with gene therapy treatment centers, channel partners, and manufacturers.
- Assist with legal review of pre-commercial activities, including advisory boards, patient engagement events, patient support programs, market access activities, speaker programs, and market research.
- Provide legal support to Beam's promotional material review committees.
- Provide ongoing contracting support and lifecycle management, including agreement interpretation and risk analysis, for commercial, medical affairs, manufacturing, and other teams.
- Collaborate with business teams and subject matter experts on continuous review and updates of Beam contracting playbooks and standards.
- Draft and negotiate other key agreements supporting Beam's broader business, including licensing agreements, collaborations, clinical trial agreements, and sponsored research agreements.
- Experience advising medical affairs and commercial teams on legal and regulatory requirements related to product launches.
- Ability to provide legal counsel on health care laws, such as anti-kickback, false claims, and transparency statutes.
- Service on promotional material review committees for pre-commercial or commercial biotechnology companies.
About the company
Beam Therapeutics uses base editing to develop precision genetic medicines aimed at correcting disease-causing mutations. It focuses on R&D and collaborates with pharmaceutical companies and research institutions to fund and advance therapies, earning revenue through partnerships, licensing, upfront and milestone payments, and royalties. The company targets genetic disorders such as sickle cell disease with the goal of delivering lifelong cures, differentiating itself through its emphasis on durable genetic remedies and a science-driven, values-led culture.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Get referred to Beam Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Beam got Sixth Street's $500 million facility in February 2026.
- First patient dosed in BEAM-302 pivotal cohort August 2026.
- Cash plus facility fund operations into mid-2029.
What critics are saying
- Beam sued YolTech and Serapha on September 25, 2026 over stolen trade secrets.
- Any BEAM-302 or risto-cel clinical setback kills the platform's valuation.
- AATD competitors Serapha and Wave pressure pricing, capital, and first-mover advantage.
What makes Beam Therapeutics unique
- Beam owns base-editing IP plus integrated delivery/manufacturing, enabling single-base corrections without double-strand breaks.
- BEAM-302 showed durable AAT biomarker correction, and FDA feedback supports accelerated approval.
- Risto-cel published NEJM data and targets year-end 2026 BLA submission.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Beam Therapeutics sues YolTech and Serapha Bio over base editing secrets. Beam Therapeutics has taken two Chinese scientists and their employers, YolTech and Serapha Bio, to court over alleged trade secret theft, putting its base editing platform at the centre of a cross-border IP... Beam Therapeutics, the Cambridge, Massachusetts developer of CRISPR base editing therapies, has filed suit against two Chinese scientists and the two biotech companies employing them, YolTech and Serapha Bio, alleging theft of Beam's trade secrets and copying of its gene editing technology. Beam Therapeutics, the Cambridge, Massachusetts company built around CRISPR base editing, has gone to court against two Chinese scientists and the two biotech companies that employ them, alleging they took Beam's trade secrets and reproduced its gene editing technology. The defendant companies are named as YolTech and Serapha Bio, according to Endpoints News. Shares in Beam (ticker: BEAM) were quoted at 24.52, up 1.20% on the day, as of 20:00 GMT on 29 September 2026, with a session range of 23.88 to 24.76 against a previous close of 24.23. The move was modest and in line with a mixed tape: the S&P 500 tracker (SPY) was at $764.20, down 0.18%, while the Nasdaq 100 proxy (QQQ) held $737.93, up 0.19%. What base editing is, and why the recipe matters. Conventional CRISPR works by cutting both strands of DNA and letting the cell's repair machinery do the rest. Base editing, the approach Beam has built its pipeline on, avoids the double-strand break: it chemically converts one DNA letter into another at a targeted site. That is a far more surgical operation, and in principle a safer one, but it depends on a stack of know-how that does not show up in a patent filing - the exact editor protein variants, the guide RNA designs that work and the ones that quietly fail, the delivery formulations, the screening data that tells you which candidate to advance and which to abandon. That accumulated, unpublished knowledge is precisely what trade secret law is designed to protect, and it is what Beam says was taken. Patents describe an invention in public; trade secrets protect the parts a competitor would otherwise have to spend years and a great deal of money rediscovering. A claim of misappropriation is therefore an assertion that a rival skipped the queue rather than an argument about who invented what first. A cross-border case with practical limits. Suing individuals and companies with operations in China introduces complications that a purely domestic trade secret case does not have. Service of process, discovery of documents held abroad, and - should Beam prevail - enforcement of any judgment or injunction against assets outside the United States all become live questions. In practice, the most immediate leverage in cases of this kind is often not a damages award but the chilling effect on a defendant's ability to raise capital in Western markets, partner with US or European pharmaceutical companies, or run clinical trials under US regulatory oversight while litigation is pending. That is the part investors in Beam should watch. A trade secret suit rarely resolves quickly, and the near-term financial consequence for the plaintiff is legal spend, not revenue. What it can do is complicate a competitor's path to the same commercial markets Beam intends to serve. How the market read it. The share price reaction says the equity market treated this as a governance and positioning story rather than a valuation event. A 1.20% gain on the day, inside a range of 23.88 to 24.76, is ordinary trading for a clinical-stage biotech; it is not the kind of move that follows a readout or a regulatory decision. Litigation news of this type typically does not re-rate a platform company, because nothing about the pipeline, the cash position or the trial calendar changed on the day of filing. The share price reaction says the equity market treated this as a governance and positioning story rather than a valuation event. Still, the filing carries signalling value. Companies do not sue former scientific personnel and their new employers casually - the process is expensive, it invites countersuits, and discovery can expose the plaintiff's own internal records. Bringing the action suggests Beam believes it can identify specific protected material and trace it, which is the threshold question in any misappropriation claim. The wider pattern in gene editing. Gene editing has been unusually litigious from the start, and most of the high-profile fights have been patent interference disputes over foundational CRISPR claims between academic institutions and their spinouts. This case is a different species. It is about employee mobility and what departing scientists carry with them - in their notebooks, on their devices, and in their heads - rather than about who filed first at the patent office. It also reflects a structural shift in the sector. Chinese biotechs have moved rapidly from fast-following to originating, and Western developers increasingly find themselves competing against programmes that reach the clinic quickly and at lower cost. Trade secret litigation is one of the few tools available to a US company that believes the speed came from somewhere it should not have. What to watch from here. * Venue and jurisdiction rulings. Whether the court accepts jurisdiction over foreign-domiciled defendants will shape how far the case can actually travel. * Any request for preliminary relief. An early injunction motion would signal Beam thinks the harm is ongoing rather than historic. * Responses from YolTech and Serapha Bio. Denials, motions to dismiss, or counterclaims will indicate how hard the defence intends to fight. * Partnering activity. Whether large pharmaceutical companies pause or proceed with deals involving the named defendants is the clearest real-world read on how seriously the allegations are taken. * Beam's own disclosures. Legal expense and any quantified damages claim would surface in subsequent filings. Allegations in a complaint are allegations. None of the claims described here has been tested in court, and the defendants have not, on the available record, responded. For now the substance of the dispute is a set of assertions about how a competitor acquired the know-how behind one of biotechnology's more valuable platforms - and the answer will take considerably longer to arrive than the market's one-day verdict on the stock. Key facts. * Beam share price: BEAM at 24.52, +1.20%, as of 20:00 GMT 29 Sep 2026 * Defendants named: YolTech, Serapha Bio and two Chinese scientists * Claim: Theft of trade secrets and copying of Beam's gene editing technology * Beam's technology: CRISPR base editing, developed from Cambridge, Massachusetts Frequently asked questions. Who has Beam Therapeutics sued? Beam Therapeutics has sued two Chinese scientists and the two biotech companies where they work, named in the complaint as YolTech and Serapha Bio. The suit alleges the defendants stole Beam's trade secrets and copied its gene editing technology. Beam is based in Cambridge, Massachusetts and develops CRISPR base editing therapies. What is base editing and how does it differ from standard CRISPR? Standard CRISPR cuts both strands of DNA at a target site and relies on the cell's repair machinery. Base editing instead chemically converts one DNA letter into another without making a double-strand break. It is a more precise operation that depends heavily on proprietary know-how: editor protein variants, guide RNA designs, delivery formulations and screening data. How did Beam's shares react to the lawsuit? Beam shares were quoted at 24.52 as of 20:00 GMT on 29 September 2026, up 1.20% on the day from a previous close of 24.23, trading in a range of 23.88 to 24.76. That is an ordinary session for a clinical-stage biotech and suggests the market did not treat the filing as a valuation event. Why sue over trade secrets rather than file a patent claim? Patents make an invention public in exchange for exclusivity, but much of a platform's practical value sits in unpublished know-how - which formulations work, which candidates failed, and why. Trade secret law protects that material. A misappropriation claim asserts a rival skipped years of costly discovery rather than disputing who invented something first. What makes suing companies with Chinese operations difficult? Cross-border cases raise hurdles around serving legal papers on foreign defendants, obtaining discovery of documents held abroad, and enforcing any eventual judgment or injunction against assets outside US jurisdiction. In practice the leverage often comes less from damages than from the effect on a defendant's ability to raise Western capital or partner with US and European pharmaceutical firms. What should investors watch next in this case? Key markers include whether the court accepts jurisdiction over foreign-domiciled defendants, whether Beam seeks preliminary injunctive relief, how YolTech and Serapha Bio respond through motions or counterclaims, whether large pharmaceutical partners pause deals involving the named defendants, and what legal expense Beam discloses in subsequent filings. Trade secret litigation typically takes years to resolve.
CRISPR Therapeutics outlook: scaling gene editing by 2036. Key takeaways. * CRISPR Therapeutics currently reports $10.2 million in quarterly revenue against a $91.2 million net loss, highlighting the heavy R&D burden of its current pipeline. * The company is pivoting from ex-vivo therapies like Casgevy toward in-vivo editing, which could expand its addressable patient population from 150,000 to 400,000. * By 2036, the success of SyNTase editing and in-vivo delivery methods will determine if the firm transitions from a niche biotech to a diversified genomic medicine powerhouse. TrendPulse analysis. Industry context. The gene-editing landscape is moving beyond the "proof of concept" phase into a period of rigorous commercial validation. Historically, the sector has been defined by high-cost, one-time curative treatments. However, the industry is now facing a "delivery bottleneck." Competitors like **Intellia Therapeutics** and **Beam Therapeutics** are also racing to solve the in-vivo delivery challenge, as the market increasingly favors standardized, off-the-shelf products over the bespoke, patient-specific manufacturing processes that currently dominate the space. Furthermore, the regulatory environment is becoming more sophisticated. As seen with recent setbacks at major pharmaceutical firms like **Novartis**, regulators are no longer satisfied with biomarker improvements alone. They now demand clear, long-term clinical outcomes that translate into tangible patient health benefits. This shift forces companies like CRISPR Therapeutics to prove not just that they can edit a gene, but that the edit reliably prevents disease progression in real-world settings. The industry is effectively moving from a "technology-first" mindset to a "clinical-outcome-first" mandate. Why this matters. For investors and industry stakeholders, the next decade represents a transition from speculative growth to operational maturity. The primary risk is no longer just scientific failure, but commercial viability. If CRISPR Therapeutics successfully transitions to in-vivo delivery, it will fundamentally change the economics of the business, moving from a high-cost service model to a scalable product model. This would likely trigger a wave of M&A activity, as large-cap pharmaceutical companies look to acquire proven, scalable genomic platforms to replenish their aging pipelines. However, the path to 2036 is fraught with "clinical disconnect" risks - where the editing works, but the patient outcome does not improve as expected. Decision-makers should monitor the company's ability to manage its cash burn while navigating these long-term trials. The winners in this space will be those who can balance the high costs of R&D with a clear, cost-effective path to commercialization. Investors should look for evidence of manufacturing efficiency and partnerships that can handle the global distribution of these complex therapies once they reach the market. The bottom line. CRISPR Therapeutics' long-term value hinges on its ability to transition from complex, ex-vivo procedures to scalable in-vivo therapies that deliver measurable, long-term clinical outcomes. Read the full article. This analysis is based on reporting from nasdaq Finance AI-powered news analysis · September 18, 2026 Editorially Reviewed
Beam Therapeutics appoints Eric Foster as CCO. 1 September 2026 Beam Therapeutics (Nasdaq: BEAM), a Cambridge, Massachusetts-based biotech developing precision genetic medicines through base editing, announced Tuesday the appointment of Eric Foster (pictured above) as chief commercial officer (CCO). Mr Foster will lead Beam's commercial organization and strategy as the company advances multiple candidates across its hematology and genetic disease franchises toward potential launches. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 26 August 2026 24 August 2026 1 September 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 1 September 2026 Company spotlight. A Shanghai-based clinical-stage biotech building a next-generation antibody-drug conjugate pipeline across four proprietary platforms, with a BLA accepted in China and a BioNTech partnership worth over $1.5 billion in potential milestones. More features in biotechnology. 1 September 2026
Cayenne Wellness Center announces 5th annual Hispanic Heritage Month Educational Summit in Long Beach. Aug 17, 2026 The event brings Hispanic Heritage Month and National Sickle Cell Awareness Month together to advance education, health equity, advocacy, and access to care GLENDALE, CA, August 17, 2026 /24-7PressRelease/ - Join New Jersey News Today in commemorating two significant months with a blend of impactful programming, deep community connections, and shared momentum for change. New Jersey News Today is thrilled to acknowledge the vital role of its sponsors in bringing these celebrations to life, starting with its headline supporters. Cayenne Wellness Center proudly recognizes the invaluable contribution of its key sponsors as New Jersey News Today gear up for upcoming events honoring National Sickle Cell Awareness Month and Hispanic Heritage Month. Beam Therapeutics, Inc. stands tall as a GOLD sponsor, while Chiesi USA, Inc. and Global Rare Diseases graciously serve as its SILVER sponsors for the Hispanic Heritage Summit on September 15 to 16, 2026, at the Marriott Long Beach Downtown in Long Beach, California. Event Details: Dates: September 15-16, 2026 Location: Long Beach, CA & Online Target Audience: Designed for healthcare professionals, educators, social workers, students, Hispanic and Latino individuals and families affected by sickle cell disease, and members of the broader community. The two-day educational summit aims to unite sickle cell warriors, caregivers, healthcare professionals, advocates, community leaders, organizations, and families to shed light on sickle cell disease. It will also specifically address the unique experiences and challenges faced by Hispanic and Latino individuals and families affected by the condition. The summit will feature culturally relevant education, community voices, advocacy, and dialogue focused on improving awareness, health equity, and access to quality sickle cell care. The timing of this year's summit carries special significance. September is National Sickle Cell Awareness Month, a time dedicated to increasing understanding of sickle cell disease and elevating the voices and experiences of those living with the condition. The summit also begins on September 15, the opening of Hispanic Heritage Month, creating a timely opportunity to bring greater visibility to the intersection of culture, health, identity, and sickle cell disease. Programming will explore the relationship between country of origin, genetic background, and community-centered sickle cell education, while providing practical tools to help warriors advocate for themselves and navigate sickle cell disease, comorbidities, and related health concerns. A central part of the summit will be the inclusion of lived experience. A warrior-led roundtable will create space for individuals living with sickle cell disease to share their perspectives and experiences directly with attendees. The program will also address the important transition from pediatric to adult care, and feature breakout discussions focused on men's health and sickle cell disease, women's health and sickle cell disease, international sickle cell warriors, and domestic and international providers and caregivers. Beyond the educational sessions, the summit is designed to strengthen relationships across the sickle cell community. Vendor and exhibitor tables are available for community-based organizations, businesses, healthcare organizations, authors, artists, educational institutions, industry partners, and others interested in sharing resources and connecting directly with summit participants. Through education, storytelling, advocacy, resource-sharing, and community connection, Cayenne Wellness Center's Hispanic Heritage Month Educational Summit aims to expand awareness of sickle cell disease within Hispanic and Latino communities and strengthen pathways to culturally responsive information, resources, support, and care. Registration Is Now Open Sickle cell warriors, families, caregivers, healthcare professionals, advocates, community organizations, and other interested attendees are invited to participate. Register to attend: https://cayennewellness.org/espanol/hispanic-heritage-virtual-seminar-2026 Vendor & Exhibitor Opportunities Organizations and businesses interested in connecting with attendees are invited to reserve a vendor or exhibitor table. Opportunities are available for community organizations, healthcare organizations, authors, artists, businesses, educational institutions, and industry partners. Reserve a vendor or exhibitor table: https://tinyurl.com/HHVENDOR2026 Cayenne Wellness Center and Children's Foundation is a 501(c)(3) nonprofit organization established in 2000 and dedicated to improving the quality of life for individuals living with sickle cell disease in California. The organization provides expert, unbiased, and comprehensive care while promoting education, advocacy, and awareness for healthcare providers, patients, and the wider community. With a strong grassroots network and a commitment to equity, Cayenne Wellness continues to be a trusted leader in advancing sickle cell support and resources. Learn more and get involved at CayenneWellness.org. Follow Cayenne Wellness Center on: Facebook: facebook.com/CayenneWellness Instagram: instagram.com/CayenneWellness X (formerly Twitter): @CayenneWellness YouTube: youtube.com/@CayenneWellness Read the original story here: https://www.24-7pressrelease.com/press-release/537770/cayenne-wellness-center-announces-5th-annual-hispanic-heritage-month-educational-summit-in-long-beach Press Release Service and Press Release Distribution by 24-7 Press Release Newswire Looking for Local Media Coverage in the United States of America? New Jersey News Today has a place for all 50 States at the State News Network
Beam Therapeutics (NASDAQ:BEAM) downgraded by Wall Street Zen to "Strong Sell" August 16, 2026 Key points. * Wall Street Zen downgraded Beam Therapeutics to "Strong Sell" from "Sell," although the broader analyst consensus remains "Moderate Buy" with an average price target of $49. * Beam reported weaker-than-expected quarterly results, including an adjusted loss of $1.18 per share versus estimates of $1.11 and revenue of $0.49 million versus expectations of $16.37 million; revenue fell 94.2% year over year. * The stock opened at $26.75, below its 50-day average of $30.26, while insiders sold roughly $10.5 million worth of shares over the past 90 days. * MarketBeat previews top five stocks to own in September. Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Sunday. BEAM has been the subject of a number of other research reports. Sanford C. Bernstein lowered their price target on Beam Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reissued a "buy" rating on shares of Beam Therapeutics in a report on Monday, August 10th. Bank of America restated a "buy" rating and issued a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $49.00. Beam Therapeutics trading up 0.9%. NASDAQ BEAM opened at $26.75 on Friday. Beam Therapeutics has a 12-month low of $15.60 and a 12-month high of $38.26. The company has a fifty day simple moving average of $30.26 and a two-hundred day simple moving average of $28.80. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2.76 billion, a P/E ratio of -31.10 and a beta of 2.23. Discover more Stocks & Bonds Stock average calculator Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.07). Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company had revenue of $0.49 million for the quarter, compared to analysts' expectations of $16.37 million. During the same period last year, the firm earned ($1.00) earnings per share. Beam Therapeutics's quarterly revenue was down 94.2% compared to the same quarter last year. On average, analysts forecast that Beam Therapeutics will post -4.49 earnings per share for the current year. Insider buying and selling at Beam Therapeutics. In other news, insider Fmr Llc sold 251,488 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $35.26, for a total value of $8,867,466.88. Following the sale, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Amy Simon sold 16,667 shares of the firm's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $25.74, for a total value of $429,008.58. Following the sale, the insider directly owned 85,696 shares in the company, valued at approximately $2,205,815.04. This trade represents a 16.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is owned by corporate insiders. Hedge funds weigh in on Beam Therapeutics. Several institutional investors have recently made changes to their positions in BEAM. Jones Financial Companies Lllp boosted its holdings in Beam Therapeutics by 55,780.0% during the first quarter. Jones Financial Companies Lllp now owns 33,528 shares of the company's stock worth $655,000 after buying an additional 33,468 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Beam Therapeutics by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 438,529 shares of the company's stock worth $8,564,000 after acquiring an additional 42,609 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Beam Therapeutics during the 2nd quarter worth about $201,000. New York State Common Retirement Fund boosted its stake in shares of Beam Therapeutics by 17.7% during the 2nd quarter. New York State Common Retirement Fund now owns 30,629 shares of the company's stock worth $521,000 after acquiring an additional 4,600 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Beam Therapeutics by 46.0% during the 2nd quarter. Invesco Ltd. now owns 128,874 shares of the company's stock worth $2,192,000 after acquiring an additional 40,583 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors. About Beam Therapeutics. Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need. Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Beam Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list. While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.